Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine

Inclusion Criteria:

• Participants who are medically healthy with no clinically significant or relevantabnormalities as determined by medical history, physical or neurologicalexamination, vital signs, 12-lead ECG, screening clinical laboratory profiles (hematology, biochemistry, coagulation, and urinalysis), as deemed by theInvestigator or designee.

• Body weight of at minimum 50 kg and body mass index (BMI) within the range 18 to 32kg/m^2 (inclusive) at the Screening.

• Male and female participants should adhere to the protocol defined contraceptivemethods.

Exclusion Criteria:

• History or presence of medical (eg, cardiovascular, respiratory, hepatic, renal,gastrointestinal, endocrinological, hematological, neurological or other disorders)or psychiatric conditions or diseases.

• History of clinically significant hypersensitivity or idiosyncratic reaction to thestudy drugs or related compounds.

• History of drug or alcohol abuse within 2 years prior to first dosing

• Current tobacco users or smokers (defined as any tobacco or nicotine-containingproduct use within 3 months prior to first dosing).

• Donation of whole blood from 3 months prior to first dose administration, or ofplasma from 30 days before first dose administration.

• Female participants who have a positive pregnancy test at Screening or Day -1, orwho are lactating.

• Positive drugs of abuse, cotinine, or alcohol screen at Screening or Day -1.